Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Shares Down 1.8% – Time to Sell?

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI – Get Free Report) traded down 1.8% during mid-day trading on Wednesday. The company traded as low as $1.05 and last traded at $1.09. 2,669,901 shares traded hands during trading, an increase of 5,524% from the average daily volume of 47,476 shares. The stock had previously closed at $1.11.

Calidi Biotherapeutics Price Performance

The firm has a 50-day simple moving average of $1.45 and a two-hundred day simple moving average of $2.71. The company has a market capitalization of $2.92 million, a price-to-earnings ratio of -0.02 and a beta of 1.32. The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.24.

Get Calidi Biotherapeutics alerts:

Calidi Biotherapeutics (NYSEAMERICAN:CLDI – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($2.94) earnings per share (EPS) for the quarter.

About Calidi Biotherapeutics

(Get Free Report)

Calidi Biotherapeutics, Inc is a clinical-stage biotechnology company developing stem cell-based therapies designed to improve the delivery and effectiveness of cancer treatments. The company’s approach uses allogeneic stem cells as protective carriers that can transport therapeutic agents into tumors while helping shield those agents from the body’s immune system.

Calidi’s technology platforms include NeuroNova, which is based on neural stem cells, and SuperNova, which uses engineered allogeneic stem cells.

See Also

• Five stocks we like better than Calidi Biotherapeutics
• Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
• Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
• Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
• Oil May Be Stronger Than It Looks—And Diamondback Is on Sale

Receive News & Ratings for Calidi Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calidi Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.